Literature DB >> 21792729

MIBG scintigraphy in differential diagnosis of Parkinsonism: a meta-analysis.

Giorgio Treglia1, Ernesto Cason, Antonella Stefanelli, Fabrizio Cocciolillo, Daniela Di Giuda, Giorgio Fagioli, Alessandro Giordano.   

Abstract

OBJECTIVE: Differential diagnosis between Parkinson's disease (PD) and other Parkinsonism using clinical criteria or imaging methods is often difficult. The purpose of this study is to systematically review and meta-analyze published data about the diagnostic performance of myocardial innervation imaging using (123)I-metaiodobenzylguanidine (MIBG) scintigraphy in differential diagnosis between PD and other Parkinsonism.
METHODS: A comprehensive computer literature search of studies published through March 2011 regarding MIBG scintigraphy in patients with PD and other Parkinsonism was performed in PubMed/MEDLINE and Embase databases. Only studies in which MIBG scintigraphy was performed for differential diagnosis between PD and other Parkinsonism were selected. Pooled sensitivity, pooled specificity and area under the ROC curve were calculated to measure the accuracy of MIBG scintigraphy in differential diagnosis between PD and other Parkinsonism.
RESULTS: Nineteen studies comprising 1,972 patients (1,076 patients with PD, 117 patients with other Lewy body diseases and 779 patients with other diseases) were included in this meta-analysis. The pooled sensitivity of MIBG scintigraphy in detecting PD was 88% (95% CI 86-90%); the pooled specificity of MIBG scintigraphy in discriminating between PD and other Parkinsonism was 85% (95% CI 81-88%). The area under the ROC curve was 0.93.
CONCLUSIONS: In patients with clinically suspected PD, myocardial innervation imaging demonstrated high sensitivity and specificity. MIBG scintigraphy is an accurate test in this setting. Nevertheless, possible causes of false-negative and false-positive results should be kept in mind when interpreting the scintigraphic results.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21792729     DOI: 10.1007/s10286-011-0135-5

Source DB:  PubMed          Journal:  Clin Auton Res        ISSN: 0959-9851            Impact factor:   4.435


  49 in total

1.  Cardiac uptake of [123I]MIBG separates Parkinson's disease from multiple system atrophy.

Authors:  S Braune; M Reinhardt; R Schnitzer; A Riedel; C H Lücking
Journal:  Neurology       Date:  1999-09-22       Impact factor: 9.910

Review 2.  123I-metaiodobenzylguanidine scintigraphy in Parkinson's disease and related disorders.

Authors:  Olivier Rascol; Ludwig Schelosky
Journal:  Mov Disord       Date:  2009       Impact factor: 10.338

3.  Diagnostic cutoff points for ¹²³I-MIBG myocardial scintigraphy in a Caucasian population with Parkinson's disease.

Authors:  Africa Muxí; Pilar Paredes; Ignacio Navales; Francesc Valldeoriola; Carles Gaig; Francisco Lomeña; Andres de la Cerda; Oriol Solà; Beatriz Domenech; Eduardo Tolosa; Francesca Pons
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-03-04       Impact factor: 9.236

4.  Sensitivity and specificity of metaiodobenzylguanidine (MIBG) myocardial accumulation in the diagnosis of Lewy body diseases in a movement disorder clinic.

Authors:  Fuyuki Tateno; Ryuji Sakakibara; Masahiko Kishi; Emina Ogawa; Hitoshi Terada; Tsuyoshi Ogata; Hiroyuki Haruta
Journal:  Parkinsonism Relat Disord       Date:  2011-02-20       Impact factor: 4.891

5.  Clinical and neuropathological correlates of Lewy body disease.

Authors:  Nozomi Hishikawa; Yoshio Hashizume; Mari Yoshida; Gen Sobue
Journal:  Acta Neuropathol       Date:  2003-01-14       Impact factor: 17.088

Review 6.  The role of cardiac metaiodobenzylguanidine uptake in the differential diagnosis of parkinsonian syndromes.

Authors:  S Braune
Journal:  Clin Auton Res       Date:  2001-12       Impact factor: 4.435

7.  Validation of cardiac (123)I-MIBG scintigraphy in patients with Parkinson's disease who were diagnosed with dopamine PET.

Authors:  Kenji Ishibashi; Yuko Saito; Shigeo Murayama; Kazutomi Kanemaru; Keiichi Oda; Kiichi Ishiwata; Hidehiro Mizusawa; Kenji Ishii
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01       Impact factor: 9.236

8.  Cardiac MIBG scintigraphy is a sensitive tool for detecting cardiac sympathetic denervation in Parkinson's disease.

Authors:  Frédéric Courbon; Christine Brefel-Courbon; Claire Thalamas; Marie-Jeanne Alibelli; Isabelle Berry; Jean-Louis Montastruc; Olivier Rascol; Jean-Michel Senard
Journal:  Mov Disord       Date:  2003-08       Impact factor: 10.338

9.  123I-MIBG cardiac scintigraphy provides clues to the underlying neurodegenerative disorder in idiopathic REM sleep behavior disorder.

Authors:  Tomoyuki Miyamoto; Masayuki Miyamoto; Keisuke Suzuki; Momoka Nishibayashi; Masaoki Iwanami; Koichi Hirata
Journal:  Sleep       Date:  2008-05       Impact factor: 5.849

10.  Combined use of DAT-SPECT and cardiac MIBG scintigraphy in mixed tremors.

Authors:  Fabiana Novellino; Gennarina Arabia; Antonio Bagnato; Giuseppe Lucio Cascini; Maria Salsone; Giuseppe Nicoletti; Demetrio Messina; Maurizio Morelli; Sandra Paglionico; Laura Giofrè; Antonino Restuccia; Giusi Torchia; Francesca Condino; Aldo Quattrone
Journal:  Mov Disord       Date:  2009-11-15       Impact factor: 10.338

View more
  35 in total

1.  Thyroid blockade in 123I-mIBG cardiac imaging: A common sense approach.

Authors:  Arnold F Jacobson
Journal:  J Nucl Cardiol       Date:  2015-05-14       Impact factor: 5.952

2.  Comparison of I-123 MIBG planar imaging and SPECT for the detection of decreased heart uptake in Parkinson disease.

Authors:  Jin-Kyoung Oh; Eun-Kyoung Choi; In-Uk Song; Joong-Seok Kim; Yong-An Chung
Journal:  J Neural Transm (Vienna)       Date:  2015-05-24       Impact factor: 3.575

Review 3.  Imaging the Autonomic Nervous System in Parkinson's Disease.

Authors:  Karoline Knudsen; Per Borghammer
Journal:  Curr Neurol Neurosci Rep       Date:  2018-09-19       Impact factor: 5.081

Review 4.  Modeling and imaging cardiac sympathetic neurodegeneration in Parkinson's disease.

Authors:  Valerie Joers; Marina E Emborg
Journal:  Am J Nucl Med Mol Imaging       Date:  2014-03-20

5.  Potential diagnostic value of regional myocardial adrenergic imaging using (123)I-MIBG SPECT to identify patients with Lewy body diseases.

Authors:  Adrien Lebasnier; Guillaume Lamotte; Alain Manrique; Damien Peyronnet; Gerard Bouvard; Gilles Defer; Denis Agostini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-01-28       Impact factor: 9.236

6.  Septal penetration in iodine-123 metaiodobenzylguanidine cardiac sympathetic imaging using a medium-energy collimator.

Authors:  Yusuke Inoue; Yutaka Abe; Yuji Asano; Kei Kikuchi; Takahiro Iizuka; Kazutoshi Nishiyama
Journal:  J Nucl Cardiol       Date:  2013-10-23       Impact factor: 5.952

7.  An improved method for estimating the heart-to-mediastinum ratio from cardiac sympathetic nerve imaging with low-energy high-resolution collimators.

Authors:  Yusuke Inoue; Yutaka Abe; Yuji Asano; Kei Kikuchi; Keiji Matsunaga; Takahiro Iizuka; Kazutoshi Nishiyama
Journal:  J Nucl Cardiol       Date:  2014-04-09       Impact factor: 5.952

8.  Reduced cardiac 123I-metaiodobenzylguanidine uptake in patients with spinocerebellar ataxia type 2: a comparative study with Parkinson's disease.

Authors:  Anna De Rosa; Sabina Pappatà; Teresa Pellegrino; Maria Fulvia De Leva; Gennaro Maddaluno; Giovanni Fiumara; Raffaella Carotenuto; Mario Petretta; Alessandro Filla; Giuseppe De Michele; Alberto Cuocolo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-08-09       Impact factor: 9.236

9.  123I-MIBG myocardial scintigraphy for the evaluation of Lewy body disease: are delayed images essential? Is visual assessment useful?

Authors:  Fumi Sakamoto; Shinya Shiraishi; Noriko Tsuda; Koji Ogasawara; Morikatsu Yoshida; Hideaki Yuki; Mamoru Hashimoto; Seiji Tomiguchi; Manabu Ikeda; Yasuyuki Yamashita
Journal:  Br J Radiol       Date:  2016-05-25       Impact factor: 3.039

10.  Sensitivity and specificity of cardiac metaiodobenzylguanidine scintigraphy in the early diagnosis of Parkinson's disease.

Authors:  Sebastian J Brandl; Stefan Braune
Journal:  Clin Auton Res       Date:  2018-06-05       Impact factor: 4.435

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.